AI platform for CT coronary angiography applications
Official title: AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)
Run by National Heart Centre Singapore · NCT05509010 · Data updated 2026-11-12
This study is testing a new AI platform that helps doctors quickly and accurately analyze heart scans for patients with coronary artery disease to improve their treatment and care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years to 80 Years |
| Sex | All |
| Enrollment | 8000 (estimated) |
| Sponsor | National Heart Centre Singapore Academic / other |
| Drugs / interventions | radiation |
| Locations | 3 sites (Singapore and 2 other locations) |
| Status | Recruiting |
| Started | October 1, 2021 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | August 19, 2022 |
| Trial ID | NCT05509010 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 21 and older who are clinically indicated for evaluation by CT coronary angiography.
✕Probably not a fit
Patients with known complex congenital heart disease or those requiring immediate invasive angiography for reasons other than CAD may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop an AI-driven national platform for CT coronary angiography that automates the processes of anonymization, reporting, Agatston scoring, and plaque quantification in patients with coronary artery disease (CAD). By leveraging artificial intelligence, the platform seeks to enhance diagnostic accuracy and efficiency, reducing the time required for report generation and minimizing inter-observer variability. The initiative addresses the growing prevalence of CAD and aims to improve clinical management and prognosis through better prediction of pharmacotherapy responses.
Why it matters
Potential benefit: If successful, this platform could significantly streamline the diagnostic process for CAD, leading to improved patient outcomes and more effective treatment strategies.
How similar studies have gone: Other studies have shown success with AI applications in medical imaging, indicating a promising potential for this approach in improving CAD diagnostics.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥21 years old 2. Signed informed consent 3. Clinically indicated for evaluation by CTCA Exclusion Criteria: 1. Individuals unable to provide informed consent 2. Known complex congenital heart disease 3. Planned invasive angiography for reasons other than CAD 4. Non-cardiac illness with life expectancy \< 2 years 5. Pregnancy 6. Concomitant participation in another clinical trial in which subject is subject to investigational drug or device 7. Cardiac event and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) and/or valvular repair/replacement prior to CTCA 8. Glomerular Filtration Rate ≤ 30mL/min 9. Known allergy to iodinated contrast agent 10. Contraindications to beta blockers or nitroglycerin or adenosine
Where it's running
-
National Heart Centre Singapore
Singapore, Singapore Recruiting -
National University Hospital
Singapore, Singapore Recruiting -
Tan Tock Seng Hospital
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Liang Zhong — National Heart Centre Singapore
- Study coordinator: Associate Professor Zhong Liang
- Email: zhong.liang@nhcs.com.sg
- Phone: +65 6704 2237
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PCI Registry at University Hospital Basel for Complex Coronary Procedures
This registry collects real-world data from adults undergoing percutaneous coronary interventions at University Hospital Basel to see how different treatments like drug-eluting stents, drug-coated balloons, and bioresorbable scaffolds perform in diverse patients.
-
SiroMax sirolimus-coated balloon for small coronary vessels with or without prior stents
A first-in-human test to see if the SiroMax drug-coated balloon can safely open narrow coronary arteries in adults with or without prior stents.
-
QFR-guided virtual stenting to optimize PCI before the procedure
We’re testing whether using QFR-based virtual stenting before PCI can improve heart-procedure outcomes compared with standard angiography planning in adults with coronary artery disease.
-
Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients
This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.
-
Comparing heart surgery and medical management for patients with aortic stenosis and coronary artery disease
This study is testing whether combining heart surgery with medical treatment is better for patients who have both aortic stenosis and coronary artery disease.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.